506 656
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.03.031 .References
[1]
Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2016: a review of current American Cancer Society guide- lines and current issues in cancer screening. CA Cancer J Clin 2016;66:96–114.[2]
Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005;23:8146–51.[3]
Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669–76.[4]
Rebbeck TR. Precision prevention of cancer. Cancer Epidemiol Biomarkers Prev 2014;23:2713–5.[5]
Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev 2014;33:413–27.[6]
Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24:1967–2000.[7]
Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resis- tance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015;15:701–11.
[8]
Azzouni F, Mohler J. Role of 5 a -reductase inhibitors in prostate cancer prevention and treatment. Urology 2012;79:1197–205.
[9]
Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutaste- ride on the risk of prostate cancer. N Engl J Med 2010;362: 1192–202.[10]
Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.[11]
Thompson Jr IM, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 2013;369:603–10.
[12]
Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5 a -reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ 2013;346:f3406.[13]
Finelli A, Trottier G, Lawrentschuk N, et al. Impact of 5 a -reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol 2011;59:509–14.
[14]
Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double- blind, placebo-controlled trial. Lancet 2012;379:1103–11.[15]
Irshad S, Bansal M, Castillo-Martin M, et al. A molecular signature predictive of indolent prostate cancer. Sci Transl Med 2013;5: 202ra122.[16]
Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999;13:966–77.
[17]
Kim MJ, Cardiff RD, Desai N, et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2002;99:2884–9.
[18]
Park JH, Walls JE, Galvez JJ, et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol 2002;161:727–35.[19]
Dutta A, Le Magnen C, Mitrofanova A, Ouyang X, Califano A, Abate- Shen C. Identification of an NKX3.1-G9a-UTY transcriptional regu- latory network that controls prostate differentiation. Science 2016;352:1576–80.
[20]
Gleave M, Qian J, Andreou C, et al. The effects of the dual 5 a - reductase inhibitor dutasteride on localized prostate cancer— results from a 4-month pre-radical prostatectomy study. Prostate 2006;66:1674–85.[21]
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome- wide expression profiles. Proc Natl Acad Sci U S A 2005;102: 15545–50.
[22]
Aytes A, Mitrofanova A, Lefebvre C, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 2014;25:638–51.
[23]
Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002;62:2999–3004.[24]
Opoku-Acheampong AB, Nelsen MK, Unis D, Lindshield BL. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. PLoS One 2012;7:e29068.
[25]
Lei Q, Jiao J, Xin L, et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 2006;9:367–78.
[26]
Tan PY, Chang CW, Chng KR, Wansa KD, Sung WK, Cheung E. Integration of regulatory networks by NKX3-1 promotes andro- gen-dependent prostate cancer survival. Mol Cell Biol 2012;32: 399–414.
[27]
Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-defi- cient prostate cancer. Cancer Cell 2011;19:575–86.[28]
Mitrofanova A, Aytes A, Zou M, Shen MM, Abate-Shen C, Califano A. Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models. Cell Rep 2015;12:2060–71.
[29]
Le Magnen C, Dutta A, Abate-Shen C. Optimizing mouse models for precision cancer prevention. Nat Rev Cancer 2016;16:187–96.
[30]
Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913–23.[31]
Sboner A, Demichelis F, Calza S, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010;3:8.[32]
Wang X, Kruithof-de Julio M, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009;461:495–500.[33]
Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011–25.
[34]
Bowen C, Bubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111–5.
[35]
Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer 2015;15:747–56.
[36]
Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. The APL paradigm and the ‘‘co-clinical trial’’ project. Cancer Discov 2011;1:108–16.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 4 9 9 – 5 0 6
506